Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling.

Challenger JD, Bruxvoort K, Ghani AC, Okell LC.

Nat Commun. 2017 Nov 9;8(1):1373. doi: 10.1038/s41467-017-01352-3.

2.
3.

Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures.

van der Pluijm RW, Watson J, Woodrow CJ.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00721-17. doi: 10.1128/AAC.00721-17. Print 2017 Jul. No abstract available.

PMID:
28655744
4.

Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa.

Zwang J, D'Alessandro U, Ndiaye JL, Djimdé AA, Dorsey G, Mårtensson AA, Karema C, Olliaro PL.

BMC Infect Dis. 2017 Jun 23;17(1):443. doi: 10.1186/s12879-017-2530-6.

5.

Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.

Nambozi M, Kabuya JB, Hachizovu S, Mwakazanga D, Mulenga J, Kasongo W, Buyze J, Mulenga M, Van Geertruyden JP, D'Alessandro U.

Malar J. 2017 May 16;16(1):199. doi: 10.1186/s12936-017-1851-7.

6.

Demography, maternal health and the epidemiology of malaria and other major infectious diseases in the rural department Tsamba-Magotsi, Ngounie Province, in central African Gabon.

Manego RZ, Mombo-Ngoma G, Witte M, Held J, Gmeiner M, Gebru T, Tazemda B, Mischlinger J, Groger M, Lell B, Adegnika AA, Agnandji ST, Kremsner PG, Mordmüller B, Ramharter M, Matsiegui PB.

BMC Public Health. 2017 Jan 28;17(1):130. doi: 10.1186/s12889-017-4045-x.

7.

Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.

Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, Tachibana SI, Auma M, Ntege EH, Ito D, Takashima E, Palacpac NM, Egwang TG, Onen JO, Kataoka M, Kimura E, Horii T, Tsuboi T.

Malar J. 2017 Jan 9;16(1):23. doi: 10.1186/s12936-016-1663-1.

8.

Four artemisinin-based treatments in African pregnant women with malaria.

PREGACT Study Group, Pekyi D, Ampromfi AA, Tinto H, Traoré-Coulibaly M, Tahita MC, Valéa I, Mwapasa V, Kalilani-Phiri L, Kalanda G, Madanitsa M, Ravinetto R, Mutabingwa T, Gbekor P, Tagbor H, Antwi G, Menten J, De Crop M, Claeys Y, Schurmans C, Van Overmeir C, Thriemer K, Van Geertruyden JP, D'Alessandro U, Nambozi M, Mulenga M, Hachizovu S, Kabuya JB, Mulenga J.

Malawi Med J. 2016 Sep;28(3):139-149.

10.

In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo.

de Wit M, Funk AL, Moussally K, Nkuba DA, Siddiqui R, Bil K, Piriou E, Bart A, Bahizi Bizoza P, Bousema T.

Malar J. 2016 Sep 6;15:455. doi: 10.1186/s12936-016-1444-x.

12.

Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda.

Chang HH, Meibalan E, Zelin J, Daniels R, Eziefula AC, Meyer EC, Tadesse F, Grignard L, Joice RC, Drakeley C, Wirth DF, Volkman SK, Buckee C, Bousema T, Marti M.

Sci Rep. 2016 May 20;6:26330. doi: 10.1038/srep26330.

13.

In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014.

Paczkowski M, Mwandama D, Marthey D, Luka M, Makuta G, Sande J, Ali D, Troell P, Mathanga DP, Gutman J.

Malar J. 2016 Apr 26;15:236. doi: 10.1186/s12936-016-1281-y.

14.

Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.

Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, Oduro A, Macete E, Abdulla S, Halidou T, Sie A, Osei I, Sevene E, Asante KP, Mulokozi A, Compaore G, Valea I, Adjuik M, Baiden R, Ogutu B, Binka F, Gyapong M.

Malar J. 2016 Jan 27;15:43. doi: 10.1186/s12936-016-1099-7.

15.

Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial.

Kremsner PG, Adegnika AA, Hounkpatin AB, Zinsou JF, Taylor TE, Chimalizeni Y, Liomba A, Kombila M, Bouyou-Akotet MK, Mawili Mboumba DP, Agbenyega T, Ansong D, Sylverken J, Ogutu BR, Otieno GA, Wangwe A, Bojang KA, Okomo U, Sanya-Isijola F, Newton CR, Njuguna P, Kazungu M, Kerb R, Geditz M, Schwab M, Velavan TP, Nguetse C, Köhler C, Issifou S, Bolte S, Engleitner T, Mordmüller B, Krishna S.

PLoS Med. 2016 Jan 12;13(1):e1001938. doi: 10.1371/journal.pmed.1001938. eCollection 2016 Jan.

16.

Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.

Toure OA, Rulisa S, Anvikar AR, Rao BS, Mishra P, Jalali RK, Arora S, Roy A, Saha N, Iyer SS, Sharma P, Valecha N.

Malar J. 2015 Nov 25;14:469. doi: 10.1186/s12936-015-0982-y.

17.

Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.

Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ.

J Infect Dis. 2016 Apr 1;213(7):1134-42. doi: 10.1093/infdis/jiv551. Epub 2015 Nov 23.

18.

Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.

Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M.

Trop Med Int Health. 2016 Feb;21(2):224-35. doi: 10.1111/tmi.12642. Epub 2015 Dec 16.

19.

Budget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania.

Mori AT, Norheim OF, Robberstad B.

Pharmacoeconomics. 2016 Mar;34(3):303-14. doi: 10.1007/s40273-015-0344-1.

20.

Inclusion of gametocyte parameters in anti-malarial drug efficacy studies: filling a neglected gap needed for malaria elimination.

Abdul-Ghani R, Basco LK, Beier JC, Mahdy MA.

Malar J. 2015 Oct 19;14:413. doi: 10.1186/s12936-015-0936-4.

Supplemental Content

Support Center